--- title: "Biohaven: Broad Late-Stage Pipeline Supports Buy Rating and Unchanged $21 Price Target" type: "News" locale: "en" url: "https://longbridge.com/en/news/295527656.md" description: "Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Biohaven Ltd. with an unchanged $21 price target, citing its broad late-stage pipeline including opakalim and taldefgrobep-alfa. He views the assets as de-risked with multiple value-creation opportunities despite higher R&D spending. Additionally, Bank of America Securities reiterated a Buy rating with a $11 price target." datetime: "2026-08-11T11:06:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295527656.md) - [en](https://longbridge.com/en/news/295527656.md) - [zh-HK](https://longbridge.com/zh-HK/news/295527656.md) generator: "portal-rs" --- # Biohaven: Broad Late-Stage Pipeline Supports Buy Rating and Unchanged $21 Price Target Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Biohaven Ltd. yesterday and set a price target of $21.00. ### Claim 55% Off TipRanks - Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions - Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Sumant Kulkarni has given his Buy rating due to a combination of factors tied to Biohaven’s late-stage pipeline and valuation. He highlights that pivotal data for opakalim in focal epilepsy and taldefgrobep-alfa in obesity are expected in the second half of 2026, and he views opakalim’s drug class as relatively de-risked given the high unmet need in focal epilepsy. Kulkarni also emphasizes Biohaven’s broad pipeline, including newly advanced Phase 3 programs BHV-1300 for Graves’ disease and BHV-1400 for IgA nephropathy, plus BHV-8000 for Parkinson’s disease, which together provide multiple value-creation opportunities. While acknowledging higher-than-modeled R&D spending, he maintains a discounted cash flow–based valuation that supports an unchanged $21 price target, arguing the current share price does not fully reflect the potential of these assets. According to TipRanks, Kulkarni is a 5-star analyst with an average return of 13.7% and a 49.60% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Zevra Therapeutics, Definium Therapeutics, and COMPASS Pathways. In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $11.00 price target. ### Related Stocks - [BHVN.US](https://longbridge.com/en/quote/BHVN.US.md) - [ZVRA.US](https://longbridge.com/en/quote/ZVRA.US.md) - [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md) - [CMPS.US](https://longbridge.com/en/quote/CMPS.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) ## Related News & Research - [Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement?](https://longbridge.com/en/news/296708698.md) - [RBC Capital Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)](https://longbridge.com/en/news/295524380.md) - [TD Cowen Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)](https://longbridge.com/en/news/295624079.md) - [CTS Eventim: Buy Rating Reiterated as Strong Q2 Results and Ticketing Growth Support Unchanged $100 Price Target](https://longbridge.com/en/news/296525048.md) - [Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP](https://longbridge.com/en/news/296018014.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**